This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Upchurch, G. R. Articles by Loscalzo, J. Search for Related Content PubMed PubMed Citation Articles by Upchurch, G. R., Jr Articles by Loscalzo, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Thinners Hazardous Substances DB HEPARIN NITRIC OXIDE PROTAMINE

(Circulation. 1997;95:2115-2121.)
© 1997 American Heart Association, Inc.

Articles

High-Dose Heparin Decreases Nitric Oxide Production by Cultured Bovine Endothelial Cells

Gilbert R. Upchurch, Jr, MD; George N. Welch, MD; Jane E. Freedman, MD; Attila J. Fabian, PhD; Alessio Pigazzi, AB; Anne M. Scribner, AB; Caroline S. Alpert, AB; John F. Keaney, Jr, MD; Joseph Loscalzo, MD, PhD

From the Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine (G.R.U., G.N.W., J.E.F., A.J.F., A.P., A.M.S., C.S.A., J.F.K., J.L.), and Department of Surgery, Brigham and Women's Hospital, Harvard Medical School (G.R.U.), Boston, Mass.

Correspondence to Joseph Loscalzo, MD, PhD, Whitaker Cardiovascular Institute, Boston University School of Medicine, 80 E Concord St, W-507, Boston, MA 02118.

Background Abrupt cessation of heparin therapy can lead to a recrudescence of thrombosis and acute ischemia. Endothelial NO is an important endogenous inhibitor of platelet-mediated thrombosis, yet biochemical studies examining the effect of heparin on NO production by the endothelium have heretofore been lacking.

Methods and Results In an attempt to address the effect of heparin on endothelial cell production of NO, confluent bovine aortic endothelial cells (BAECs) on microcarrier beads were incubated in the presence or absence of heparin. Results indicate that BAECs incubated with heparin were less able to inhibit platelet aggregation than control cells (P<.005 by ANOVA) and that this effect correlated with a decrease in NO production (36% decrease for heparin compared with control, P<.05). Dextran sulfate evoked the same response (67% decrease, P<.0001 compared with control), suggesting that the decrease in NO after heparin treatment is secondary to its negative charge rather than to a specific polysaccharide sequence. The decrease in NO production by heparin was accompanied by a 72% decrease in steady-state Nos 3 mRNA as well as a 49% decrease in immunodetectable endothelial NO synthase (eNOS) protein.

Conclusions These data show that high-dose heparin at concentrations achieved in some acute cardiovascular settings increases in vitro platelet aggregation in media conditioned by endothelial cells by decreasing endothelial NO production through a mechanism that involves a decrease in steady-state Nos 3 mRNA and eNOS protein. These observations suggest a possible mechanism by which to explain in part the prothrombotic effects of heparin.

Key Words: heparin • anticoagulants • endothelium • endothelium-derived factors • thrombosis

This article has been cited by other articles:

				J. W.G.E. VanTeeffelen, J. Brands, C. Jansen, J. A.E. Spaan, and H. Vink Heparin Impairs Glycocalyx Barrier Properties and Attenuates Shear Dependent Vasodilation in Mice Hypertension, July 1, 2007; 50(1): 261 - 267. [Abstract] [Full Text] [PDF]

				M. Johnell, G. Elgue, R. Larsson, A. Larsson, S. Thelin, and A. Siegbahn Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 321 - 332. [Abstract] [Full Text] [PDF]

				G. Fragasso, P. M. Piatti, L. Monti, A. Palloshi, C. Lu, G. Valsecchi, E. Setola, G. Calori, G. Pozza, A. Margonato, et al. Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: Evaluation of the protective role of the metabolic modulator trimetazidine J. Am. Coll. Cardiol., February 6, 2002; 39(3): 413 - 419. [Abstract] [Full Text] [PDF]

				G. R. Upchurch Jr, D. G. Goodman, S. R. Willoughby, Y.-Y. Zhang, G. N. Welch, J. E. Freedman, S. Ye, C. E. Costello, and J. Loscalzo Heparin Reacts With and Inactivates Nitric Oxide Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 163 - 173. [Abstract] [PDF]

				T. Bachetti, E. Pasini, E. Clini, G. Cremona, and R. Ferrari High-Dose Heparin Impairs Nitric Oxide Pathway and Vasomotion in Rats Circulation, June 8, 1999; 99(22): 2861 - 2863. [Abstract] [Full Text] [PDF]

				P. C. Kouretas, Y. D. Kim, P. A. Cahill, A. K. Myers, L. N. To, Y.-N. Wang, J. V. Sitzmann, and R. L. Hannan Nonanticoagulant Heparin Prevents Coronary Endothelial Dysfunction After Brief Ischemia-Reperfusion Injury in the Dog Circulation, March 2, 1999; 99(8): 1062 - 1068. [Abstract] [Full Text] [PDF]

				J. E. Freedman, B. Ting, B. Hankin, J. Loscalzo, J. F. Keaney Jr, and J. A. Vita Impaired Platelet Production of Nitric Oxide Predicts Presence of Acute Coronary Syndromes Circulation, October 13, 1998; 98(15): 1481 - 1486. [Abstract] [Full Text] [PDF]

				F. I Hawari, B. E Shykoff, and J. L Izzo Jr Heparin attenuates norepinephrine-induced venoconstriction Vascular Medicine, May 1, 1998; 3(2): 95 - 100. [Abstract] [PDF]

				D. J. Horstman, L. G. Fischer, P. C. Kouretas, R. L. Hannan, and G. F. Rich Role of nitric oxide in heparin-induced attenuation of hypoxic pulmonary vascular remodeling J Appl Physiol, May 1, 2002; 92(5): 2012 - 2018. [Abstract] [Full Text] [PDF]

				T. C. Woods, C. R. Blystone, J. Yoo, and E. R. Edelman Activation of EphB2 and Its Ligands Promotes Vascular Smooth Muscle Cell Proliferation J. Biol. Chem., January 11, 2002; 277(3): 1924 - 1927. [Abstract] [Full Text] [PDF]